Amneal Pharmaceuticals (DB:2DT) - Aandelenkoers, Nieuws & Analyse

2DT Overzicht aandelen

2DT fundamentele analyse
Sneeuwvlok Score
Waardering	6/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Verhandeld tegen 81.8% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 5.57% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Analisten zijn het erover eens dat de aandelenkoers met 24% zal stijgen

Risicoanalyse

Negatief eigen vermogen

Volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Amneal Pharmaceuticals, Inc. Concurrenten

Dermapharm Holding

XTRA:DMP

€1.9b

Bayer

XTRA:BAYN

€19.9b

PharmaSGP Holding

XTRA:PSG

€297.4m

Pierrel

DB:2FJ0

€92.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Amneal Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$8.05
52 Week Hoogtepunt	US$8.55
52 Week Laag	US$3.80
Bèta	1.17
11 maand verandering	5.23%
3 maanden verandering	17.52%
1 Jaar Verandering	102.26%
33 jaar verandering	101.25%
5 jaar verandering	198.15%
Verandering sinds IPO	-56.27%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	2DT	DE Pharmaceuticals	DE Markt
7D	5.9%	-7.5%	-0.2%
1Y	102.3%	-24.1%	8.3%

Rendement versus industrie: 2DT overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -24.1 % opleverde.

Rendement versus markt: 2DT overtrof de German markt, die het afgelopen jaar een rendement opleverde van 8.3 %.

Prijsvolatiliteit

Is 2DT's price volatile compared to industry and market?
2DT volatility
2DT Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	8.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 2DT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van 2DT is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2002	7,850	Chirag Patel	amneal.com

Amneal Pharmaceuticals, Inc. ontwikkelt, produceert, verkoopt en distribueert samen met zijn dochterondernemingen wereldwijd generieke geneesmiddelen, injecteerbare geneesmiddelen, biosimilars en farmaceutische specialiteiten onder merknaam. Het bedrijf is actief in drie segmenten: Generieken, Specialiteiten en AvKARE. Het segment Generieken biedt vaste, poeder-, vloeibare, steriele injecteerbare, neusspray-, inhalatie- en respiratoire, biosimilaire, oogheelkundige, film-, transdermale pleister- en lokale producten voor directe en verlengde afgifte.

Amneal Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Amneal Pharmaceuticals zich tot de beurswaarde?
2DT fundamentele statistieken
Marktkapitalisatie	€2.65b
Inkomsten(TTM)	-€175.21m
Inkomsten(TTM)	€2.55b

1.0x

P/S-verhouding

-14.2x

Koers/Winstverhouding

Is 2DT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2DT resultatenrekening (TTM)
Inkomsten	US$2.68b
Kosten van inkomsten	US$1.70b
Brutowinst	US$979.05m
Overige uitgaven	US$1.16b
Inkomsten	-US$184.45m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.60
Brutomarge	36.53%
Nettowinstmarge	-6.88%
Schuld/Eigen Vermogen Verhouding	-7,524.6%

Hoe presteerde 2DT op de lange termijn?

Bekijk historische prestaties en vergelijking

2DT Overzicht aandelen

Beloningen

Risicoanalyse

Amneal Pharmaceuticals, Inc. Concurrenten

XTRA:DMP

€1.9b

XTRA:BAYN

€19.9b

XTRA:PSG

€297.4m

DB:2FJ0

€92.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold €236k worth of stock

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022)

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Insufficient new directors

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021)

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021)

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021)

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

High number of new directors